Theodore Karrison to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Theodore Karrison has written about Neoplasm Recurrence, Local.
Connection Strength
0.990
-
Estimation of progression-free survival in the randomized discontinuation trial design. J Clin Oncol. 2013 Feb 20; 31(6):814.
Score: 0.283
-
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
Score: 0.117
-
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
Score: 0.116
-
Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999 Jan 06; 91(1):80-5.
Score: 0.107
-
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
Score: 0.086
-
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
Score: 0.059
-
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70.
Score: 0.045
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.040
-
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
Score: 0.037
-
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
Score: 0.034
-
Treatment of ductal carcinoma in situ. N Engl J Med. 1999 Sep 23; 341(13):999-1000.
Score: 0.028
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
Score: 0.020
-
The pathological findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer. 1982 Nov 15; 50(10):2131-8.
Score: 0.009
-
Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy. JAMA. 1982 Sep 17; 248(11):1337-41.
Score: 0.009